Disease Overview：Platelet Storage Pool Disease（PSPD）
Platelet storage pool disease (PSPD) is a rare inherited or acquired bleeding disorder characterized by quantitative or qualitative defects in platelet dense granules or alpha granules—key organelles responsible for storing and releasing adenosine diphosphate (ADP), serotonin, calcium, fibrinogen, von Willebrand factor, and other hemostatic mediators. Patients typically present with mild-to-moderate mucocutaneous bleeding—epistaxis, menorrhagia, easy bruising, and prolonged bleeding after trauma or surgery—despite normal platelet counts and routine coagulation tests (PT/aPTT). Diagnosis relies on specialized assays including platelet aggregation studies (showing impaired response to epinephrine and ADP), electron microscopy for granule ultrastructure, and flow cytometry for granule-specific markers (e.g., CD63 for dense granules). Management is largely supportive: antifibrinolytics (tranexamic acid), desmopressin (DDAVP) for select cases, and avoidance of antiplatelet agents; platelet transfusions are reserved for major hemorrhage or invasive procedures.
China offers distinct advantages for PSPD evaluation and management. Leading hematologic centers—such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital—host multidisciplinary thrombosis and hemostasis units with expertise in rare platelet disorders, validated diagnostic protocols, and access to advanced flow cytometry, transmission electron microscopy, and next-generation sequencing for genetic subtyping. Success rates in symptom control and perioperative bleeding prevention align with international benchmarks, supported by over 120 documented PSPD cases managed annually across tier-1 institutions. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromise in diagnostic rigor or therapeutic standards. As a dedicated medical tourism agency, we facilitate seamless care for international patients: pre-travel clinical review, direct coordination with certified hematologists, transparent itemized pricing (including diagnostics, consultations, and follow-up), visa support, interpreter services, and post-discharge telemedicine continuity—all designed to reduce uncertainty and optimize outcomes.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Platelet Storage Pool Disease (Hematology)
Non-Surgical / Conservative / Medication Options
*Target Criteria:* Mild–moderate bleeding (e.g., menorrhagia, easy bruising, mucocutaneous bleeding), no life-threatening hemorrhage, preserved platelet count and aggregation.
- •Desmopressin (DDAVP) Infusion (IV)
- *Fee Breakdown (per dose):* - Drug (15 µg vial): $28–$35 - IV administration + nursing time: $12–$18 - Pre-infusion PTT/platelet function assay (Verify absence of VWF deficiency): $42–$56
- •Antifibrinolytic Therapy (Tranexamic Acid)
- *Fee Breakdown (7-day course):* - Oral tablets (1 g × 3/day): $8–$11 - Baseline renal function (Cr, eGFR) + CBC: $24–$32
- •Hormonal Management (for women)
- *Fee Breakdown (3-month initiation):* - Combined oral contraceptive (levonorgestrel/ethinylestradiol): $15–$22 - Pelvic ultrasound (to exclude structural pathology): $38–$49 - Liver enzyme panel (ALT/AST): $18–$25
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Severe, recurrent, or life-threatening hemorrhage unresponsive to medical therapy; documented platelet dense granule deficiency via electron microscopy or ATP release assay.
- •Platelet Transfusion (Leukoreduced, ABO/Rh-matched)
- *Fee Breakdown (1 unit, ~3–4 × 10¹¹ platelets):* - Platelet unit (screened, irradiated if indicated): $185–$230 - Pre-transfusion HLA/antibody screen (if history of refractoriness): $68–$89 - Post-transfusion platelet count + functional assay (24h): $52–$67
- •Splenectomy (Laparoscopic)
- *Fee Breakdown:* - Preoperative workup (Tc-99m platelet scan, CT abdomen, coagulation panel): $210–$275 - Surgery + anesthesia + 3-day hospital stay: $3,200–$4,100 - Post-op platelet count monitoring × 7 days: $45–$60
Special / Complex Condition Options
- •Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
- *Fee Breakdown (full cycle):* - Donor matching (HLA typing × 4 loci): $195–$255 - Conditioning regimen (fludarabine/melphalan): $1,450–$1,820 - Inpatient HSCT admission (28 days avg.): $12,800–$15,600
Quick Selection Guide
- •Children <12 years, mild symptoms: Start with tranexamic acid + DDAVP as needed ($40–$90 total initial outlay)
- •Adult women with menorrhagia, budget <$200: Hormonal therapy + tranexamic acid ($50–$75/month)
- •Severe bleeding, comorbid ITP or refractory transfusions: Splenectomy ($3,400–$4,400) — avoid if IgA deficiency or asplenia contraindicated
- •Elderly (>75), multiple comorbidities: Conservative DDAVP + tranexamic acid only; avoid splenectomy or HSCT
- •Young adult with life-threatening hemorrhage + failed transfusions: Urgent splenectomy ($3,400–$4,400) — HSCT reserved for proven dual-lineage failure
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Platelet Storage Pool Disease Medical Vacation Packages
Curated transparent all-inclusive packages combining Platelet Storage Pool Disease treatment with China top medical destinations:
